Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Production & Manufacturing
Fine & Speciality Chemicals
Return to: PBR Home | Production & Manufacturing | Fine & Speciality Chemicals | Suppliers

Johnson Matthey Fine Chemicals – Complex Chemistry, Simply Delivered News

Johnson Matthey Fine Chemicals – Complex Chemistry, Simply Delivered

Johnson Matthey Launches New Online Catalyst Store West Deptford, N.J. – 11 January 2017, Johnson Matthey (LSE: JMAT), a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, is pleased to announce the launch of its new online catalyst store
View press release
Johnson Matthey's Annan, UK site receives MHRA certification for GMP manufacturing The company has made significant investments to refurbish the site, which is now fully equipped for GMP manufacturing
View press release
Johnson Matthey Acquires Pharmaceutical Manufacturing Capacity in Scotland, UK Johnson Matthey (LSE: JMAT), a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, has announced completion of an acquisition of pharmaceutical manufacturing capacity in Scotland, U.K. The 109,000 sq. metre site was acquired to meet increasing demand for custom pharmaceutical services and active ingredients utilising enhanced manufacturing capabilities.
View press release
Johnson Matthey Commissions New High Containment Manufacturing Capacity in Edinburgh, UK Johnson Matthey (LSE: JMAT), a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, has announced completion and commissioning of new high containment facilities for potent product manufacture at its Edinburgh, UK site (Macfarlan Smith).
View press release
Johnson Matthey Rebrands its Fine Chemicals Division Johnson Matthey (LSE: JMAT), a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, has today unveiled the distinctive new branding for its Fine Chemicals Division. The new brand brings together Johnson Matthey’s broad chiral and catalysis technologies, its world-leading opiates and narcotics capabilities, and global API development, life cycle management and manufacturing expertise.
View press release
Johnson Matthey Receives Two Pharmaceutical and Biotech CMO Leaderships Awards 2015 Johnson Matthey (LSE: JMAT), a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, has been recognised in the 2015 CMO Leadership Awards for the Reliability and Regulatory Track record of its Pharma Services to the Biotech Industry.
View press release
Johnson Matthey Acquires Pharmorphix Johnson Matthey (LSE: JMAT), a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, has acquired the Pharmorphix® solid form research business from Sigma-Aldrich. This acquisition brings world-leading material science capabilities to Johnson Matthey’s expanding European API and clinical supply services.
View press release
Low Conversion In Your Cross-Coupling Reaction? Try Our New Phosphine "pi-allyl" Palladium Catalysts For Unprecedented Results.
View press release
Join us for a One Day Symposium to Discover our Latest Technologies and Services Johnson Matthey Catalysis and Chiral Technologies is hosting a one day technical symposium. We invite you to attend our one day technical symposium to be held on Tuesday, 16th June 2015.
View press release
Heterogeneous Catalyst 40 Sample Kit Instant Availability to 40 Heterogeneous Catalyst Types.
View press release
Johnson Matthey Catalysis and Chiral Technologies Introduces Catalytic Reaction Guide Mobile Application Johnson Matthey Catalysis and Chiral Technologies (JMCCT), a business unit of Johnson Matthey Fine Chemical Division, has announced the launch of its Catalytic Reaction Guide (CRG) as a free mobile application.
View press release
Johnson Matthey Acquires Pharmaceutical Manufacturing Capacity in Scotland Johnson Matthey, a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, has announced completion of an acquisition of pharmaceutical manufacturing capacity in Scotland, U.K. The 109,000 sq. metre site was acquired to meet increasing demand for custom pharmaceutical services and active ingredients utilising enhanced manufacturing capabilities.
View press release
ACS Announces Dr Thomas Colacot as the Recipient of the 2015 National Award for Industrial Chemistry Johnson Matthey is pleased to announce that Dr. Thomas Colacot, Global R&D manager of Homogeneous Catalysis for the Johnson Matthey Catalysis and Chiral Technologies (JMCCT) business unit, has been awarded the 2015 American Chemical Society (ACS) National Award for Industrial Chemistry. This honour is further recognition of Dr. Colacot’s contribution to the area of catalysis, having received an award for Applied Catalysis from the Royal Society of Chemistry in 2012.
View press release
Attending CPhI 2014?. There's Still Time to Book a Meeting with us. Johnson Matthey Catalysis and Chiral Technologies is exhibiting at CPhI 2014 at stand 6F29.
View press release
Put Our Phosphine Ru AMPY Catalyst to the Test Finally, a Real Alternative to Hydride Reduction.
View press release
JMCCT Introduces New Ruthenium Tethered Catalysts What is a Tethered Catalyst?
View press release
When Was the Last Time You Considered Allyl and Crotyl Palladium (II) Complexes? Air and Moisture Stable. Highly Active. Easy to Handle.
View press release
New Enzyme Kit Catalysis and Chiral Technologies' new enzyme kit contains a selection of highly active enzymes providing faster screening while maintaining maximum hit rates. Every enzyme in our kit is 100% reproducible and available at commercial scale.
View press release
Johnson Matthey Catalysis and Chiral Technologies Announces Commercial-Scale Tethered Catalyst Offer Johnson Matthey Catalysis and Chiral Technologies (JMCCT), a business unit of Johnson Matthey Fine Chemical Division (LSE: JMAT), has announced an expansion to its proprietary tethered catalyst technology, and is now offering multi-kilogram quantities for application in commercial processes.
View press release
Johnson Matthey Catalysis and Chiral Technologies Expands Ligands Offer; Boosts Buchwald Ligands Manufacturing to Commercial Scale Matthey (LSE: JMAT) has announced that their global Catalysis and Chiral Technologies technology business unit, JMCCT, which provides trusted expertise in heterogeneous, homogeneous, chiral and biocatalytic technologies for customers in the pharmaceutical, fine chemical and agrochemical industries, is expanding its existing specialty ligand manufacturing capability to include commercial-scale manufacturing up to 100kg.
View press release